Analysts Set Medpace Holdings Inc (MEDP) PT at $37.25

Shares of Medpace Holdings Inc (NASDAQ:MEDP) have earned a consensus recommendation of “Hold” from the ten research firms that are covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $37.25.

MEDP has been the topic of a number of analyst reports. Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Robert W. Baird lifted their price objective on Medpace from $32.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, October 31st. William Blair cut Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call. Jefferies Group lifted their price objective on Medpace from $34.00 to $38.00 and gave the company a “hold” rating in a research note on Wednesday, November 1st. Finally, BidaskClub cut Medpace from a “hold” rating to a “sell” rating in a research note on Tuesday, December 5th.

Shares of Medpace (MEDP) traded up $0.33 during trading on Wednesday, reaching $38.03. The company had a trading volume of 151,600 shares, compared to its average volume of 177,024. Medpace has a 52-week low of $21.76 and a 52-week high of $39.64. The stock has a market capitalization of $1,429.21, a P/E ratio of 55.93, a price-to-earnings-growth ratio of 1.62 and a beta of -0.76. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68.

In other Medpace news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $30.16, for a total transaction of $138,736,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 25.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of MEDP. Vanguard Group Inc. lifted its stake in shares of Medpace by 23.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,014,439 shares of the company’s stock worth $29,419,000 after purchasing an additional 191,597 shares during the period. Alpha Windward LLC acquired a new stake in Medpace in the 4th quarter valued at $513,000. Parametric Portfolio Associates LLC acquired a new stake in Medpace in the 2nd quarter valued at $325,000. American Century Companies Inc. acquired a new stake in shares of Medpace during the third quarter valued at about $391,000. Finally, Northern Trust Corp grew its stake in shares of Medpace by 15.9% during the second quarter. Northern Trust Corp now owns 101,728 shares of the company’s stock valued at $2,950,000 after acquiring an additional 13,938 shares in the last quarter. 20.71% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Analysts Set Medpace Holdings Inc (MEDP) PT at $37.25” was originally reported by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://weekherald.com/2018/02/19/analysts-set-medpace-holdings-inc-medp-pt-at-37-25.html.

About Medpace

Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.

Analyst Recommendations for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply